Abstract
Background/Aims
Methods
Results
Notes
Funding Source
This work was supported by the National Taiwan University Hospital (NTUH 107-A139 to Wei SC) and the Liver Disease Prevention and Treatment Research Foundation, Taiwan (to Wei SC and Weng MT).
Conflict of Interest
Wong JM and Wei SC are editorial board members of the journal but were not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.
Author Contribution
Drafting of the manuscript: Weng MT, Wei SC. Analysis and interpretation of the data: Weng MT, Shih IL, Wong JM. Acquisition of the data: Shih IL, Tung CC, Leong YL. Statistical analysis: Weng MT. Critical revision of the manuscript for important intellectual content and study supervision: Shieh MJ, Wang CY, Wong JM. Study concept and design: Wei SC, Ni YH. Approval of final manuscript: all authors.
Supplementary Material
REFERENCES
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Table 1.
Characteristics | PSC UC | Non-PSC UC | P-value |
---|---|---|---|
Age (yr) | 22.5 (12–27) | 49.0 (32–59) | 0.001a |
Male sex | 10/12 (83.3) | 217/371 (58.5) | 0.085 |
Age ≤ 16 yr | 5/5 (100) | 13/34 (38.2) | 0.015a |
Age > 16 yr | 5/7 (71.4) | 204/337 (60.5) | 0.560 |
Table 2.
Table 3.
Variable | PSC UC (n = 12) | Non-PSC UC (n = 38) | P-value |
---|---|---|---|
Underlying diseases | |||
Hypertension | 1 (8.3) | 2 (5.3) | 0.696 |
Diabetes mellitus | 0 | 2 (5.3) | 0.417 |
Hyperlipidemia | 0 | 1 (2.6) | 0.570 |
Coronary artery disease | 0 | 2 (5.3) | 0.417 |
Chronic kidney disease | 1 (8.3) | 2 (5.3) | 0.696 |
HBV carrier | 0 | 0 | - |
HCV carrier | 0 | 2 (5.3) | 0.404 |
Colitis location/extent | 0.271 | ||
Proctitis | 2 (16.7) | 4 (10.5) | |
Left side colon | 1 (8.3) | 12 (31.6) | |
Extensive | 9 (75.0) | 22 (57.9) | |
Rectal sparing | 3 (25.0) | 0 | 0.001a |
Backwash ileitis | 2/6 (33.3) | 2/22 (9.1) | 0.133 |
Disease severity | 0.513 | ||
Mild | 6 (50.0) | 15 (39.5) | |
Moderate | 2 (16.7) | 13 (34.2) | |
Severe | 4 (33.3) | 10 (26.3) | |
Liver involvement | |||
Jaundice | 6 (50.0) | 1 (2.6) | < 0.001a |
Liver cirrhosis | 5 (41.7) | 1 (2.6) | 0.001a |
Hepatic decompensation | 3 (25.0) | 1 (2.6) | 0.013a |
Transplantation | 3 (25.0) | 0 | 0.001a |
Treatment | |||
UDCA | 12 (100) | 0 | 0.001a |
5-ASA | 10 (83.3) | 38 (100) | 0.054 |
Steroid | 7 (58.3) | 20 (52.6) | 0.730 |
Thiopurine | 5 (41.7) | 18 (47.4) | 0.730 |
Anti-TNF-α | 0 | 8 (21.1) | 0.083 |
Cancer | 1 (8.3) | 3 (7.9) | 0.679 |
Mortality | 2 (16.7) | 3 (7.9) | 0.377 |
Table 4.
Parameter | PSC UC (n = 12) | Non-PSC UC (n = 38) | P-value |
---|---|---|---|
WBC (× 103/μL) | 6,145 ± 2,698 | 6,800 ± 3,493 | 0.956 |
Hb (g/dL) | 10.60 ± 1.92 | 12.40 ± 2.15 | 0.002a |
T-Bil (mg/dL) | 1.26 ± 3.40 | 0.54 ± 0.52 | 0.001a |
ALT (U/L) | 73.00 ± 172.40 | 12.00 ± 16.59 | < 0.001a |
ALP (U/L) | 275.50 ± 231.50 | 75.50 ± 99.00 | < 0.001a |
γ-GT (U/L) | 165.00 ± 111.70 | 24.50 ± 108.10 | 0.005a |
PT (sec) | 11.40 ± 5.36 | 10.90 ± 1.01 | 0.042a |
Alb (g/dL) | 3.65 ± 0.53 | 4.25 ± 1.31 | 0.092 |
Cre (mg/dL) | 0.60 ± 2.10 | 0.75 ± 0.44 | 0.246 |
CRP (mg/dL) | 1.51 ± 1.92 | 0.29 ± 2.70 | 0.626 |